A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 841 participants.
Also called NCT01128894
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 841 participants
- Sponsor
- Registry
-
NCT01128894
-
- Other papers using this trial's data
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Israel, Peru, Philippines, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01128894. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2014-05-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Biological)
- albiglutide
- Intervention (Drug)
- liraglutide
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01128894- Content hash
f0cdf32f3adceecbf5986281cf0202cd9aa70044820c81ef03d7a12ac6233dbc